Cholinergic urticaria are heat-related hives that cause raised, red spots or an itchy rash. They can occur anywhere on the body (though the neck and chest are common) and typically lead to itching.

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Phase 3 trials showed significant reductions in itch and urticaria severity with dupilumab compared to placebo at week 24. Dupilumab offers a new treatment option for CSU, being the first targeted ...

CSU is stated to be a chronic inflammatory skin condition leading to recurring itch and severe hives. Credit: Andrey_Popov/Shutterstock. Sanofi and Regeneron’s ...

Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older. Several studies reported reduced itch severity and urticaria activity with dupilumab.

Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate "safe and helpful answers" to questions posed by healthcare professionals ...

Are hives bugging you day and night? You don’t have to put up with the itch.

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and adolescents over 12 years of age in over a decade. The FDA has approved Regeneron’s ...

I had an exceptional experience from start to finish working with William Hicks at Southern Palms Mazda. He was extremely helpful, knowledgeable, and friendly during the entire process and I would ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

The winners of BloombergNEF’s annual Pioneers awards are racing to deploy the next generation of climate solutions.

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new targeted drug for the inflammatory skin disease in over a decade ...